Despite fierce competition on generic Oxaliplatin, AqVida is convinced it can generate major sales of the product due to the low level of production costs and transfer prices.

The product will be available for out-licensing in August. AqVida has confirmed talks with several interested companies throughout Europe have been initiated.

This is the third such development by the company, which was founded in 2004 and is mainly known for its bio-similar Filgrastim, which is registered under the trade name Leucita in Russia and under registration in several other countries in Eastern Europe and Latin America.